Multicenter experience of adult medulloblastoma: A study of Anatolian Society of Medical Oncology (ASMO)

Basit Öğe Kaydı
dc.authoridUysal, Mukremin/0000-0002-8524-0665
dc.authoridBilici, Ahmet/0000-0002-3192-456X
dc.authoridÖksüzoğlu Çakmak, Ömür Berna/0000-0002-2756-8646
dc.authoridbenekli, mustafa/0000-0003-3184-4946
dc.authoridGuney, Yildiz/0000-0003-2251-3571
dc.authoridDEMIRCI, UMUT/0000-0002-4833-6721
dc.authorwosidUysal, Mukremin/B-8956-2014
dc.authorwosidBilici, Ahmet/E-2062-2018
dc.authorwosidÖksüzoğlu Çakmak, Ömür Berna/HKN-6428-2023
dc.authorwosidbenekli, mustafa/AAE-4555-2020
dc.contributor.authorEsbah, Onur
dc.contributor.authorDemirci, Umut
dc.contributor.authorDane, Faysal
dc.contributor.authorGunaydsin, Yusuf
dc.contributor.authorOzdemir, Nuriye
dc.contributor.authorEkinci, Ahmet Siyar
dc.contributor.authorKodaz, Hilmi
dc.date.accessioned2024-06-12T10:50:46Z
dc.date.available2024-06-12T10:50:46Z
dc.date.issued2016
dc.departmentTrakya Üniversitesien_US
dc.description.abstractPurpose: Medulloblastoma (MB) is rarely seen in adults. For adjuvant therapy in adults the same therapy protocols used in pediatric cases are used. The present study retrospectively evaluated the data of MB patients who were treated in different Oncology Centers in Turkey. Methods: The data of 60 adult patients with MB from 8 Oncology Centers diagnosed between 2005 and 2012 were retrospectively analyzed. Results: The median patient age was 28.8 years (range 16-54). The administered chemotherapy included procarbazine-Flomustin vincristine (group A, N=31) and cyclophosphamide/ifosfamide+vincristine+cisplatin (group B, N=13). Median chemotherapy courses were 4 (range 1-8). Median progression free survival (PFS) was 76 months and median overall survival (OS) has not been reached in both groups. In young female patients and in those who received adjuvant chemotherapy, median PFS and OS were longer but without statistical significance. Mean PFS and OS were 65.9 months and 101.2 months in group A and 113.6 months and 141.6 months in group B, respectively. Conclusion: Improved survival results were obtained in women, in patients aged below 25 years, in those who underwent gross total excision (GTE) and in those who received adjuvant therapy with cyclophosphamide/ifosphamide.en_US
dc.identifier.endpage460en_US
dc.identifier.issn1107-0625
dc.identifier.issue2en_US
dc.identifier.pmid27273958en_US
dc.identifier.scopus2-s2.0-84976494353en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage456en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/18110
dc.identifier.volume21en_US
dc.identifier.wosWOS:000376829900023en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherZerbinis Medical Publen_US
dc.relation.ispartofJournal Of Buonen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAdjuvanten_US
dc.subjectAdulten_US
dc.subjectChemotherapyen_US
dc.subjectMedulloblastomaen_US
dc.subjectPrognostic-Factorsen_US
dc.subjectBrain-Tumorsen_US
dc.subjectChemotherapyen_US
dc.subjectRadiationen_US
dc.subjectRadiotherapyen_US
dc.subjectChildhooden_US
dc.subjectSurvivalen_US
dc.subjectChildrenen_US
dc.subjectTherapyen_US
dc.titleMulticenter experience of adult medulloblastoma: A study of Anatolian Society of Medical Oncology (ASMO)en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu